Weight Suppression and Weight Suppression Speed Are Associated with Clinical Characteristics Before and at the End of Treatment

e20585 Background: Chemotherapy-induced anemia (CIA) is a frequent complication of patients (pts) with cancer and could be treated with erythropoiesis-stimulating agents such darbepoetin alfa (DA). The aim of this study was to investigate the patterns of use and effect of DA to treat CIA in clinical practice conditions. Methods: This was an observational, retrospective, multicenter study performed in 58 Spanish centres. Eligible pts were ≥18 yrs, diagnosed with non-myeloid malignancies and treated with chemotherapy (CT) and DA from October 2005 to October 2006. Data on demographic and clinical characteristics, CT and radiotherapy (RT), DA administration, red blood cell (RBC) transfusions, and haemoglobin (Hb) levels were collected from DA treatment initiation up to a maximum of 16 weeks or until treatment discontinuation. Results: A total of 685 pts were included in the study. Median age was 64.66 years (range 18.54–88.95), 50.7% were women, 74.11% had ECOG status 0–1 and 71.38% had stage III/IV cancer. Solid tumours represented 72.55% of the cases. The CT regimen included platinum derivates in 33.58% of the pts. At DA initiation, mean (SD) Hb was 10.00 g/dL (1.05) Administration of DA every three weeks occurred in 54.01% of the pts. Mean (SD) DA administration was 9.20 weeks (5.31). Hematopoietic response (defined as Hb ≥ 12 g/dL or Hb rise from baseline >2 g/dL in the absence of RBC transfusions during the previous 28 days) occurred in 63.24% (95% CI 59.49–66.83) of pts. A total of 88 pts (12.85%) required RBC transfusions from week 5 to end of treatment. Mean Hb (SD) at the end of treatment with DA was 11.36 g/dL (1.73). Adverse event (AE) potentially related to DA were reported in 20 pts (2.92%) and considered severe in 6 cases (0.88%). Conclusions: The findings of this study indicate that the use of DA for the treatment of CIA in real-life, daily oncology and haematology practice, is well-tolerated and effective for increasing haemoglobin to reduce the need of RBC transfusions. [Table: see text]

Download Full-text

The impact of weight suppression and weight loss speed on baseline clinical characteristics and response to treatment

International Journal of Eating Disorders ◽

10.1002/eat.22861 ◽

2018 ◽

Vol 51 (6) ◽

pp. 542-548 ◽

Cited By ~ 6

Author(s):

Marco Solmi ◽

Davide Gallicchio ◽

Enrico Collantoni ◽

Paolo Meneguzzo ◽

Tatiana Zanetti ◽

...

Keyword(s):

Weight Loss ◽

Clinical Characteristics ◽

Response To Treatment ◽

Weight Suppression ◽

The Impact

Download Full-text

Clinical Characteristics of Pediatric with Germ Cell Tumor: Experience in a Developing Country

Althea Medical Journal ◽

10.15850/amj.v8n1.1876 ◽

2021 ◽

Vol 8 (1) ◽

Author(s):

Lelani Reniarti ◽

Anisah Febri ◽

Nur Melani Sari

Keyword(s):

Nutritional Status ◽

Germ Cell ◽

Germ Cell Tumor ◽

Clinical Characteristics ◽

Abdominal Mass ◽

Clinical Manifestations ◽

Cell Tumor ◽

Cross Sectional ◽

Common Location ◽

End Of Treatment

Background: Germ cell tumor (GCT) occurs in 3% of pregnancy malignancies and increases by 15% during adolescence. In developing countries, the five-year survival rate is 98% and 80% for GCT earlier stage and malignant tumor, respectively. This study aimed to gather information about clinical manifestations of GCT and to evaluate the treatment outcome in pediatric GCT patients at Dr. Hasan Sadikin General Hospital, Bandung, IndonesiaMethods: A descriptive cross-sectional study design with a total sampling method was conducted using secondary data from the medical record of pediatric patients diagnosed with GCT from 2015 to 2018. Data on nutritional status, clinical characteristics, histopathology stage, hematological profiles, chemical markers, treatment methods, completeness of treatment, and outcome at the end of treatment were collected and presented using tables and charts.Results: Of the 44 subjects, girls (77.3%) were predominant, with a mean age of 2 years old and normal nutritional status (59.1%). Patients generally had abdominal mass (97.7%) and most had intragonadal GCT (95.5%), with ovarium (76.2%) as the most common location. The most frequent GCT histopathology was yolk sac tumor (34.1%), with an Alpha-fetoprotein (AFP) level of >100.000 (6.8%). Almost all patients (97.7%) had undergone surgery; however, 47% of patients did not complete their treatment. At the end of treatment, the majority of patients survived (86.4%).Conclusion: Germ cell tumor has various clinical characteristics. Understanding these characteristics will enable clinicians to make a proper diagnosis and provide immediate management that will lead to a better prognosis.

Download Full-text

Low Relapse Rate after 2 Years in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP and Achieved Complete Response

Blood ◽

10.1182/blood-2018-99-119922 ◽

2018 ◽

Vol 132 (Supplement 1) ◽

pp. 2996-2996

Author(s):

Junho Kang ◽

Kyoungmin Lee ◽

Jung Yong Hong ◽

Dok Hyun Yoon ◽

Shin Kim ◽

...

Keyword(s):

Overall Survival ◽

Relapse Rate ◽

Clinical Characteristics ◽

B Cell Lymphoma ◽

Complete Response ◽

Treatment Evaluation ◽

Late Relapse ◽

Early Relapse ◽

End Of Treatment ◽

Relapse Group

Abstract Introduction : Patients with DLBCL usually relapse early after the first treatment but some relapse after 2 years (defined as late relapses). In a previous study, patients with DLBCL who achieved event free survival at 24 months had a subsequent overall survival equivalent to the general population. We analyzed the time of relapse and clinical characteristics of late relapse in patients with DLBCL who achieved complete response (CR) after frontline R-CHOP. Methods: We retrospectively reviewed prospectively collected lymphoma registry of the Asan Medical Center in Seoul, Korea, between 2002 and 2015. We found 1,047 DLBCL patients who have been treated with R-CHOP as the first line modality. Among 1,047 patients, 859 (82.0%) patients achieved CR. Chi-square or Fisher's exact test was used for comparison of categorical variables and Student's t-test or Mann-Whitney U-test for continuous variables, as appropriate. Two-sided p-value of <0.05 was considered significant. Results : Among 859 patients, 182 (21.2%) patients relapsed and 51 (5.9%) patients had late relapse after 2 years from the end of treatment evaluation that confirmed CR. For patients who had a late relapse, median time from diagnosis to relapse was 4.0 years (range, 2.0 to 10.0 years), median age was 61 years old (range, 39-78), and 27 (52.9%) patients were male. Twenty-six (51%) patients had stage I-II, and 36 (70.6%) patients had low/low-intermediate International Prognostic Index (IPI) score at diagnosis. Compared with early relapses (n=131, 12.5%), late relapses were associated with low IPI score (median, 2 vs. 3; p = 0.001), low LDH (median, 244 vs. 337 IU/L; p < 0.001), low beta-2-microglobulin (median, 2.4 vs. 2.6 mg/L p = 0.002), higher germinal center phenotype rate (30.6% vs. 15%; p=0.05). Median overall survival from the end of treatment evaluation that confirmed CR was significantly higher in the late relapse group compared with early relapse group [112.6 months (95% CI 73.1-152.0) vs. 19.9 months (95% CI 15.3-24.4); p<0.001 by log rank]. Conclusion: Our study demonstrated that relapse rate after 2 years was low (5.9%) in patients with DLBCL who achieved CR after R-CHOP. Patient with late relapse showed favorable clinical characteristics and survival outcomes compared with patients with early relapse. Disclosures No relevant conflicts of interest to declare.

Download Full-text

Quantitative characterization of Clostridioides difficile population in the gut microbiome of patients with C. difficile infection and their association with clinical factors

Scientific Reports ◽

10.1038/s41598-020-74090-0 ◽

2020 ◽

Vol 10 (1) ◽

Author(s):

Jieun Kim ◽

Youna Cho ◽

Mi-Ran Seo ◽

Mi Hyun Bae ◽

Bongyoung Kim ◽

...

Keyword(s):

Bacterial Diversity ◽

Relative Abundance ◽

Gut Microbiome ◽

Clinical Cure ◽

Clinical Characteristics ◽

Bacterial Composition ◽

Clostridioides Difficile ◽

End Of Treatment ◽

Metagenome Sequencing

Abstract Objective was to analyse bacterial composition and abundance of Clostridioides difficile in gut microbiome of patients with C. difficile infection (CDI) in association with clinical characteristics. Whole metagenome sequencing of gut microbiome of 26 CDI patients was performed, and the relative abundance of C. difficile and its toxin genes was measured. Clinical characteristics of the patients were obtained through medical records. A strong correlation between the abundance of C. difficile and tcdB genes in CDI patients was found. The relative abundance of C. difficile in the gut microbiome ranged from undetectable to 2.8% (median 0.089). Patients with fever exhibited low abundance of C. difficile in their gut, and patients with fewer C. difficile organisms required long-term anti-CDI treatment. Abundance of Bifidobacterium and Bacteroides negatively correlated with that of C. difficile at the genus level. CDI patients were clustered using the bacterial composition of the gut: one with high population of Enterococcus (cluster 1, n = 12) and another of Bacteroides or Lactobacillus (cluster 2, n = 14). Cluster1 showed significantly lower bacterial diversity and clinical cure at the end of treatment. Additionally, patients with CDI exhibited increased ARGs; notably, blaTEM, blaSHV and blaCTX-M were enriched. C. difficile existed in variable proportion of the gut microbiome in CDI patients. CDI patients with Enterococcus-rich microbiome in the gut had lower bacterial diversity and poorer clinical cure.

Download Full-text